Evidence map›Paper›PMID 38837947›Full record

ArticlePloS one2024

Associations between regional blood-brain barrier permeability, aging, and Alzheimer's disease biomarkers in cognitively normal older adults.

Marisa Denkinger, Suzanne Baker, Ben Inglis, Sarah Kobayashi, Alexis Juarez, Suzanne Mason, William Jagust

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. APOE-Targeted Therapeutics for Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marisa DenkingerHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, United States of America.ORCID 0000-0002-3696-3795
Suzanne BakerLawrence Berkeley National Laboratory, Berkeley, California, United States of America.
Ben InglisHenry H. Wheeler Jr. Brain Imaging Center, University of California, Berkeley, Berkeley, California, United States of America.
Sarah KobayashiHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, United States of America.
Alexis JuarezHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, United States of America.
Suzanne MasonHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, United States of America.
William JagustHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, United States of America.

Funding

The blood-brain barrier and Alzheimer pathologyR01AG080043 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI William J. Jagust, Daniela KAUFER · 2023 to 2026
$2.7M
Relationships between blood-brain barrier breakdown, Alzheimer's disease pathology, and memory in agingF31AG072872 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI DENKINGER, MARISA NICOLE · 2022 to 2023
$79k
NIA NIH HHS F31 AG072872NIA NIH HHS R01 AG080043
6 · The paper itself

Abstract

backgroundIncreased blood-brain barrier permeability (BBBp) has been hypothesized as a feature of aging that may lead to the development of Alzheimer's disease (AD). We sought to identify the brain regions most vulnerable to greater BBBp during aging and examine their regional relationship with neuroimaging biomarkers of AD.

methodsWe studied 31 cognitively normal older adults (OA) and 10 young adults (YA) from the Berkeley Aging Cohort Study (BACS). Both OA and YA received dynamic contrast-enhanced MRI (DCE-MRI) to quantify Ktrans values, as a measure of BBBp, in 37 brain regions across the cortex. The OA also received Pittsburgh compound B (PiB)-PET to create distribution volume ratios (DVR) images and flortaucipir (FTP)- PET to create partial volume corrected standardized uptake volume ratios (SUVR) images. Repeated measures ANOVA assessed the brain regions where OA showed greater BBBp than YA. In OA, Ktrans values were compared based on sex, Aβ positivity status, and APOE4 carrier status within a composite region across the areas susceptible to aging. We used linear models and sparse canonical correlation analysis (SCCA) to examine the relationship between Ktrans and AD biomarkers.

resultsOA showed greater BBBp than YA predominately in the temporal lobe, with some involvement of parietal, occipital and frontal lobes. Within an averaged ROI of affected regions, there was no difference in Ktrans values based on sex or Aβ positivity, but OA who were APOE4 carriers had significantly higher Ktrans values. There was no direct relationship between averaged Ktrans and global Aβ pathology, but there was a trend for an Ab status by tau interaction on Ktrans in this region. SCCA showed increased Ktrans was associated with increased PiB DVR, mainly in temporal and parietal brain regions. There was not a significant relationship between Ktrans and FTP SUVR. DISCUSSION: Our findings indicate that the BBB shows regional vulnerability during normal aging that overlaps considerably with the pattern of AD pathology. Greater BBBp in brain regions affected in aging is related to APOE genotype and may also be related to the pathological accumulation of Aβ.

Indexed as

AgingAlzheimer DiseaseBiomarkersBlood-Brain BarrierMagnetic Resonance ImagingPositron-Emission TomographyAdultAgedAged, 80 and overBrainCognitionCohort StudiesFemaleHumansMaleMiddle AgedBiomarkers

Identifiers

PMID38837947
PMCPMC11152304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.